Open Accessibility Menu

The GW Cancer Center

Washington DC Cancer & Blood Disorder Center

Receiving a diagnosis of cancer opens a world of concern and stress for the patient, the family, and friends. At the GW Cancer Center, there is peace of mind in knowing that the some of the most knowledgeable, respected, and compassionate physicians and medical staff will lead the care plan. But there is more to excellent care than outstanding staff.

The GW Cancer Center is a collaboration between The GW Medical Faculty Associates, the GW School of Medicine and Health Sciences and the GW Hospital to drive transformational research, personalized therapy, family-centered care, and cancer policy in the Nation’s Capital with the aspirational goal of achieving a cancer-free world.

A clinical components of the GW Cancer Center are located in The GW Medical Faculty Associates buildings located at 2150 Pennsylvania Avenue, NW and M Streets, NW. They provide a comprehensive approach to the diagnosis and treatment of cancer and include the GW Cancer Center Clinic, the Cyrus and Myrtle Katzen Research Center and the Comprehensive Breast Care Center.

Our Mission

The Katzen Center is committed to fostering pioneering scientific research, superior clinical care, and advanced education in order to improve the diagnosis, prevention, and treatment of cancer.

In order to achieve this mission, the Katzen Cancer Research Center seeks to provide an interdisciplinary facility to integrate basic, translational, and clinical investigators; medical educators; clinicians; health policy experts; and community leaders. In addition, the Katzen Center is dedicated to enhancing patient care through technologically advanced clinical specialties designed to contribute to the healing process. This powerful combination of academic rigor, innovative medicine, and advanced healing environment offers Washington, DC metro area patients an invaluable option for cancer care.

Our Team

The Katzen Center staff includes oncology certified physicians who are some of the region’s most renowned experts in interventional radiology, clinical oncology, basic and translational research, and psycho-oncology. We are staffed with nurses, phlebotomists (in our own blood lab), social workers, financial resource workers, patient navigators, and oncology nutritionists. The Katzen Center employs a breast and ovarian cancer genetic counselor and an oncology genetic counselor who focuses on colon, prostate, lung, and kidney cancers.

Our Collaborative Approach

The Katzen Cancer Research Center is affiliated with The George Washington University in Washington, DC, the largest institute of higher learning in the U.S. capital and renowned for both its education and research. Working in collaboration with The GW School of Medicine and Health Sciences, The GW Hospital, and The GW Medical Faculty Associates, the Katzen Center accesses the exceptional talents and resources offered by these esteemed institutions to further its mission.

Conveniently Located

Clinical Trials

  • Comparing Group Approaches to Improve Insomnia Symptoms Among Breast Cancer Survivors
    We are inviting women diagnosed with stage I-III breast cancer who have completed active treatment (e.g. surgery, chemotherapy, radiation) to participate in this research study. Through this study we will examine if our mind and body programs improve some of the long term effects of breast cancer treatment such as insomnia. This is a pilot phase of the study. This means that we are interested in feasibility of the program and will ask for your feedback about things you like and do not like about the program.
  • Combination immunotherapy with Herceptin and theHER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
    This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+
  • A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative early Breast Cancer (PALLAS Study)
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
    This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.
  • A Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for The Treatment of men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study
    The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.